We remain focused on completing enrollment in our ongoing DAYBREAK Phase 3 study to broaden the efficacy profile for tarcocimab in wet age-related macular degeneration ("wet AMD"), and it is our ...

More than 40 years ago, a pioneering study showed that hospitalised patients ... The subjects looked at different images while receiving a series of electric shocks -- some more painful than ...

Following a successful phase I study, Kodiak has advanced KSI-501 into phase III through the DAYBREAK study, which will assess its efficacy, durability and safety for wet age-related macular ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.

"With KSI-501 and its dual mechanism of action, we are exploring in the same Phase 3 DAYBREAK study the ability for KSI-501 to show a differentiated efficacy versus the active comparator aflibercept.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...